Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Xtant Medical Holdings ( (XTNT) ).
On August 12, 2025, Xtant Medical Holdings announced its second quarter 2025 financial results, reporting a total revenue of $35.4 million, an 18% increase year-over-year. The company achieved a positive net income of $3.6 million compared to a net loss in the previous year and raised its full-year 2025 revenue guidance to $131-$135 million, reflecting an 11%-15% growth over 2024. Xtant Medical also highlighted its strategic move to sell non-core spinal implant and OUS businesses to Companion Spine for approximately $19.2 million, aiming to strengthen its balance sheet and focus on its core biologics business. The launch of OsteoFactor Pro™ and Trivium™ products further positions Xtant as a leader in orthobiologic solutions, enhancing its market presence and value for shareholders.
The most recent analyst rating on (XTNT) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Xtant Medical Holdings stock, see the XTNT Stock Forecast page.
Spark’s Take on XTNT Stock
According to Spark, TipRanks’ AI Analyst, XTNT is a Neutral.
Xtant Medical Holdings shows promising revenue growth and strategic advancements, such as vertical integration and new product launches. However, financial instability due to persistent profitability and cash flow challenges, coupled with valuation concerns, weigh heavily on the score. Positive developments in corporate governance and improved earnings call sentiment provide some optimism.
To see Spark’s full report on XTNT stock, click here.
More about Xtant Medical Holdings
Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems.
Average Trading Volume: 182,598
Technical Sentiment Signal: Sell
Current Market Cap: $81.82M
Learn more about XTNT stock on TipRanks’ Stock Analysis page.